Immunovant, Inc. IMVT
33.30
(0.70)
(2.06%)
as of 25 Sep
- Market cap
- $7.1B
- P/E
- 0.0×
Follow IMVT
Insider Buys
alert about insiders buying in the last 12 month
| Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 | Mar '21 | Mar '20 | Mar '19 | Mar '18 | |
|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
9.09 | 11.16 | 13.70 | 9.34 | 11.52 | 21.79 | 7.12 | 1.94 | 0.85 |
Net Debt/EBITDA |
1.69 | 1.63 | 2.25 | 1.73 | 3.17 | 3.70 | 1.52 | 0.25 | 50.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 74.07% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.20 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.81 | 0.91 | 0.83 | 0.89 | 0.68 | 0.78 | 0.80 | 1.00 | 0.00 |
Capex/Depreciation |
(0.02) | (2.01) | (1.56) | (1.02) | (2.02) | (3.23) | (1.48) | (5.20) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (64.82%) | (62.46%) | (52.91%) | (50.69%) | (36.39%) | (44.25%) | (130.93%) | (776.77%) | (0.01%) | |
| (58.34%) | (57.37%) | (48.37%) | (45.79%) | (33.78%) | (41.17%) | (107.76%) | (401.87%) | (0.01%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (5,018.54%) | 0.00% |
Return on Tangible Assets |
(59.85%) | (59.14%) | (41.99%) | (58.38%) | (33.44%) | (27.52%) | (70.76%) | (465.48%) | 0.72% |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(2.23) | (2.48) | (1.55) | (1.53) | (0.97) | (0.95) | (1.24) | (1.29) | 0.00 |
Cash per Share |
4.95 | 4.71 | 4.60 | 3.06 | 4.50 | 4.56 | 2.33 | 0.32 | 0.02 |
Shareholders Equity per Share |
4.67 | 4.67 | 4.47 | 2.95 | 4.28 | 4.46 | 2.18 | 0.33 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
4.67 | 4.67 | 4.47 | 2.95 | 4.28 | 4.46 | 2.18 | 0.33 | 0.00 |
Free Cash Flow |
(407.32) | (376.63) | (214.59) | (188.39) | (106.37) | (83.54) | (53.39) | (28.60) | — |
Working Capital |
844.40 | 698.89 | 617.16 | 361.04 | 468.41 | 390.24 | 93.76 | 6.09 | (0.06) |
Capital Expenditures |
(0.01) | (0.76) | (0.36) | (0.20) | (0.25) | (0.21) | (0.03) | (0.05) | — |
Net Current Asset Value |
844.40 | 698.89 | 617.16 | 360.99 | 467.19 | 388.00 | 93.76 | 6.09 | (0.06) |
| Other line items | |||||||||
Quick Ratio |
8.68 | 10.42 | 13.18 | 8.72 | 11.38 | 21.38 | 6.76 | 1.53 | 0.85 |
Depreciation/Fixed assets |
0.92 | 0.45 | 0.50 | 0.58 | 0.38 | 0.32 | 0.32 | 0.19 | — |
Cash ROIC |
(23.24%) | (26.50%) | (17.13%) | (25.51%) | (11.05%) | (10.55%) | (27.45%) | (199.67%) | 0.00% |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(2.23) | (2.48) | (1.55) | (1.53) | (0.97) | (0.95) | (1.24) | (1.29) | 0.00 |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
3.23 | 4.01 | 3.19 | 6.87 | 7.00 | 2.09 | 3.00 | 3.00 | — |
Average Payables |
12.60 | 12.41 | 4.25 | 9.99 | 10.53 | 1.81 | 0.70 | 0.70 | — |
Average Assets |
866.62 | 721.29 | 536.10 | 460.70 | 464.03 | 260.94 | 61.61 | 7.12 | 7.12 |
Average Common Equity |
780.02 | 662.60 | 490.13 | 416.16 | 430.65 | 242.77 | 50.70 | 3.68 | 3.68 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates